Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ClearPoint Neuro, Inc.CLPT · Entity 2367 | Chief Financial Officer | July 09, 2020 | July 13, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ClearPoint Neuro, Inc.
Report date July 09, 2020 · Filed July 13, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 36,331 |
Reported balance
After 2020-07-09 transaction · row 1
1 source rowRow 1 · 2020-07-09 · Grant · Acquired 9,259 · Balance 36,331 F1: The shares are restricted stock and vest as follows: (i) 20% of the total shares on the first anniversary of the grant date; (ii) 40% of the total shares on the second anniversary of the grant date; and (iii) 40% of the total shares on the third anniversary of the grant date. |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.24 · Expires 2030-07-09 | Direct | 15,706 |
Reported balance
After 2020-07-09 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-07-09 · Grant · Acquired 15,706 · Balance 15,706 F2: The shares subject to this option vest as follows: (i) 20% of the total shares on the first anniversary of the grant date; (ii) 40% of the total shares on the second anniversary of the grant date; and (iii) 40% of the total shares on the third anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares are restricted stock and vest as follows: (i) 20% of the total shares on the first anniversary of the grant date; (ii) 40% of the total shares on the second anniversary of the grant date; and (iii) 40% of the total shares on the third anniversary of the grant date.
F2: The shares subject to this option vest as follows: (i) 20% of the total shares on the first anniversary of the grant date; (ii) 40% of the total shares on the second anniversary of the grant date; and (iii) 40% of the total shares on the third anniversary of the grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 09, 2020 Filed Jul 13, 2020 20:08 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantStock Options (right to buy) · Derivative | 15,706 | $0.00 Strike: $3.24 | $0.00 |
DisclosureSEC source: 0001420506-20-000714 · doc4_829.xml · derivative · entry 2 HURWITZ HAROLD A · CIK 0001241273 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,706 Underlying: Common Stock · 15,706 shares Expires 2030-07-09 F2 · derivative.exercise_date: The shares subject to this option vest as follows: (i) 20% of the total shares on the first anniversary of the grant date; (ii) 40% of the total shares on the second anniversary of the grant date; and (iii) 40% of the total shares on the third anniversary of the grant date. Read SEC document |
| July 09, 2020 Filed Jul 13, 2020 20:08 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantCommon Stock | 9,259 | $0.00 | $0.00 |
DisclosureSEC source: 0001420506-20-000714 · doc4_829.xml · nonDerivative · entry 1 HURWITZ HAROLD A · CIK 0001241273 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,331 F1 · shares: The shares are restricted stock and vest as follows: (i) 20% of the total shares on the first anniversary of the grant date; (ii) 40% of the total shares on the second anniversary of the grant date; and (iii) 40% of the total shares on the third anniversary of the grant date. Read SEC document |
| August 15, 2019 Filed Aug 19, 2019 20:07 UTC | ClearPoint Neuro, Inc. MRIC · Entity 2367 | GrantStock Options (right to buy) · Derivative | 22,321 | $0.00 Strike: $3.47 | $0.00 |
DisclosureSEC source: 0001534424-19-000242 · ownership.xml · derivative · entry 2 HURWITZ HAROLD A · CIK 0001241273 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,321 Underlying: Common Stock · 22,321 shares Expires 2029-08-15 F2 · derivative.exercise_date: The shares subject to this option vest as follows: (i) 20% of the total shares on the first anniversary of the grant date; (ii) 40% of the total shares on the second anniversary of the grant date; and (iii) 40% of the total shares on the third anniversary of the grant date. Read SEC document |
| August 15, 2019 Filed Aug 19, 2019 20:07 UTC | ClearPoint Neuro, Inc. MRIC · Entity 2367 | GrantCommon Stock | 10,806 | $0.00 | $0.00 |
DisclosureSEC source: 0001534424-19-000242 · ownership.xml · nonDerivative · entry 1 HURWITZ HAROLD A · CIK 0001241273 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,072 F1 · shares: The shares are restricted stock and vest as follows: (i) 20% of the total shares on the first anniversary of the grant date; (ii) 40% of the total shares on the second anniversary of the grant date; and (iii) 40% of the total shares on the third anniversary of the grant date. Read SEC document |
| January 23, 2019 Filed Jan 25, 2019 21:57 UTC | ClearPoint Neuro, Inc. MRIC · Entity 2367 | Tax withholdingCommon Stock | 4,092 | $2.55 | $10,434.60 |
DisclosureSEC source: 0001534424-19-000046 · ownership.xml · nonDerivative · entry 2 HURWITZ HAROLD A · CIK 0001241273 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,266 Read SEC document |
| January 23, 2019 Filed Jan 25, 2019 21:57 UTC | ClearPoint Neuro, Inc. MRIC · Entity 2367 | GrantCommon Stock | 10,011 | $0.00 | $0.00 |
DisclosureSEC source: 0001534424-19-000046 · ownership.xml · nonDerivative · entry 1 HURWITZ HAROLD A · CIK 0001241273 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,358 F1 · price: The Reporting Person received a portion of his 2018 cash bonus in the form of the Company's common stock based on the closing sales price of the Company's common stock on January 23, 2019. The shares were granted under the Company's Second Amended and Restated 2013 Incentive Compensation Plan. F2 · balance_after: This amount corrects a typographical error, which inadvertently overstated the reporting person's holdings, in the previously filed Form 4. Read SEC document |
| October 04, 2017 Filed Oct 5, 2017 20:20 UTC | ClearPoint Neuro, Inc. MRIC · Entity 2367 | GrantStock Options (right to buy) · Derivative | 20,000 | $0.00 Strike: $2.60 | $0.00 |
DisclosureSEC source: 0001534424-17-000420 · hurwitz.xml · derivative · entry 3 HURWITZ HAROLD A · CIK 0001241273 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2027-10-04 F3 · derivative.exercise_date: The shares subject to this option vest as follows: (i) one-third of the total shares on the first anniversary of the grant date; and (ii) the remaining two-thirds of the total shares ratably on a monthly basis over the 24-month period immediately following the first anniversary of the grant date. Read SEC document |
| October 04, 2017 Filed Oct 5, 2017 20:20 UTC | ClearPoint Neuro, Inc. MRIC · Entity 2367 | GrantStock Options (right to buy) · Derivative | 3,750 | $0.00 Strike: $2.60 | $0.00 |
DisclosureSEC source: 0001534424-17-000420 · hurwitz.xml · derivative · entry 2 HURWITZ HAROLD A · CIK 0001241273 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,750 Underlying: Common Stock · 3,750 shares Expires 2027-10-04 F2 · derivative.exercise_date: The shares subject to this option vest ratably in three equal installments on March 30, 2018, March 30, 2019 and March 30, 2020. Read SEC document |
| October 04, 2017 Filed Oct 5, 2017 20:20 UTC | ClearPoint Neuro, Inc. MRIC · Entity 2367 | GrantCommon Stock | 9,553 | $0.00 | $0.00 |
DisclosureSEC source: 0001534424-17-000420 · hurwitz.xml · nonDerivative · entry 1 HURWITZ HAROLD A · CIK 0001241273 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,332 F1 · price: The Reporting Person received a portion of his 2016 cash bonus in the form of the Company's common stock based on the closing sales price of the Company's common stock on October 4, 2017. The shares were granted under the Company's Second Amended and Restated 2013 Incentive Compensation Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.